Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Delayed London S.E.
Other stock markets
 03:19:33 2024-07-09 am EDT 		5-day change 1st Jan Change
271 GBX +2.26% Intraday chart for HUTCHMED (China) Limited -0.73% -4.24%
Jul. 05 Sector Update: Health Care Stocks Advance Late Afternoon MT
Jul. 05 Hutchmed's tazemetostat given priority review in China AN

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Hutchmed's tazemetostat given priority review in China
AN
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China
MT
Hong Kong Stocks Rally on US Rate Cut Hopes, EU's Indecisive on Tariffs on Chinese EVs
MT
Hutchmed's NDA for Lymphoma Drug Gets Priority Review Status in China
MT
HUTCHMED Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review
CI
Takeda's Cancer Drug Gets European Commission Approval
MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
AN
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
MT
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in the Lancet Haematology
AQ
Hutchmed celebrates "promising" results for sovleplenib in China
AN
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
AQ
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology
CI
Transcript : HUTCHMED Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Hutchmed (China) begins trial of menin inhibitor HMPL-506
AN
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia
MT
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins
MT
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. News HUTCHMED (China) Limited